MACK
Price:
$15.145
Market Cap:
$223.97M
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.[Read more]
Industry
Biotechnology
IPO Date
2012-03-29
Stock Exchange
NASDAQ
Ticker
MACK
According to Merrimack Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -35.28%. This represents a change of 811.68% compared to the average of -3.87% of the last 4 quarters.
The mean historical ROE of Merrimack Pharmaceuticals, Inc. over the last ten years is 47.04%. The current -35.28% ROE has changed -175.00% with respect to the historical average. Over the past ten years (40 quarters), MACK's ROE was at its highest in in the June 2017 quarter at 480.30%. The ROE was at its lowest in in the June 2018 quarter at -28.53%.
Average
47.04%
Median
-7.16%
Minimum
-122.85%
Maximum
490.25%
Discovering the peaks and valleys of Merrimack Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 711.33%
Maximum Annual ROE = 490.25%
Minimum Annual Increase = -114.05%
Minimum Annual ROE = -122.85%
Year | ROE | Change |
---|---|---|
2023 | -6.30% | -21.47% |
2022 | -8.02% | -53.64% |
2021 | -17.30% | -8.53% |
2020 | -18.92% | -84.60% |
2019 | -122.85% | 78.38% |
2018 | -68.87% | -114.05% |
2017 | 490.25% | 711.33% |
2016 | 60.43% | -24.88% |
2015 | 80.44% | -1.35% |
2014 | 81.55% | -72.93% |
The current ROE of Merrimack Pharmaceuticals, Inc. (MACK) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-10.54%
5-year avg
-34.68%
10-year avg
47.04%
Merrimack Pharmaceuticals, Inc.’s ROE is greater than Amicus Therapeutics, Inc. (-69.54%), greater than Celldex Therapeutics, Inc. (-21.49%), less than Achison Inc. (54.03%), less than Puma Biotechnology, Inc. (41.50%), less than Agios Pharmaceuticals, Inc. (70.20%),
Company | ROE | Market cap |
---|---|---|
-69.54% | $2.90B | |
-21.49% | $1.66B | |
54.03% | $23.73M | |
41.50% | $147.56M | |
70.20% | $1.96B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Merrimack Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Merrimack Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Merrimack Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Merrimack Pharmaceuticals, Inc. (MACK)?
What is the highest ROE for Merrimack Pharmaceuticals, Inc. (MACK)?
What is the 3-year average ROE for Merrimack Pharmaceuticals, Inc. (MACK)?
What is the 5-year average ROE for Merrimack Pharmaceuticals, Inc. (MACK)?
How does the current ROE for Merrimack Pharmaceuticals, Inc. (MACK) compare to its historical average?